Self-Assembling Lipid-Peptide Hybrid Nanoparticles of Phospholipid-Nonaarginine Conjugates for Enhanced Delivery of Nucleic Acid Therapeutics
- Authors
- Kang, Ji Hee; Battogtokh, Gantumur; Ko, Young Tag
- Issue Date
- Nov-2017
- Publisher
- AMER CHEMICAL SOC
- Citation
- BIOMACROMOLECULES, v.18, no.11, pp.3733 - 3741
- Journal Title
- BIOMACROMOLECULES
- Volume
- 18
- Number
- 11
- Start Page
- 3733
- End Page
- 3741
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/5545
- DOI
- 10.1021/acs.biomac.7b01084
- ISSN
- 1525-7797
- Abstract
- Despite potential applications of nucleic acid therapeutics, the lack of effective delivery systems hinders their clinical application. To overcome the barriers to nucleic acid delivery, we previously reported nanoparticles using phospholipid-polyethylenimine conjugates. However, toxicity of polyethylenimine remains as a problematic issue. Herein, we proposed to substitute the polyethylenimine with arginine-rich peptide to obtain a less-toxic carrier system. Nonaarginine was conjugated to the distal end of phospholipid hydrocarbon chains leading to phospholipid-nonaarginine conjugates (PL9R) and then lipid-peptide hybrid nanoparticles carrying oligonucleotide therapeutics (hNP) were constructed by self-assembly process. The hNP were further modified with cell penetrating Tat peptide (T-hNP) to enhance cellular uptake. The PL9R was less cytotoxic, and the hNP showed high loading capacity and colloidal stability. The T-hNP showed higher cellular uptake and transfection efficiency and effective accumulation to tumor tissue and silencing effect in tumor bearing mice. Altogether, T-hNP could provide a promising nanocarrier for nucleic acid therapeutics.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 약학대학 > 약학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/5545)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.